Document is current

Any future updates will be listed below

Prognostic value of natural killer cell activity for patients with HER2 + advanced gastric cancer treated with first-line fluoropyrimidine–platinum doublet plus trastuzumab

Crossref DOI link: https://doi.org/10.1007/s00262-021-03035-x

Published Online: 2021-08-22

Published Print: 2022-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark